Skip to main content
SpringerLink
Log in

We Know Accurately Only When We Know Little

  • Editorial
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. von Goethe JW [online]. Available from URL: (http://www.whale.to/a/goethe_q.html) [Accessed 2009 Dec 4]

  2. McCabe CJ. Principles of design of access with evidence development approaches: a consensus statement from the Banff summit. Pharmacoeconomics 2010; 28 (2): 109–11

    Article  PubMed  Google Scholar 

  3. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010; 28 (2): 113–42

    Article  PubMed  Google Scholar 

  4. McCabe CJ, Stafinski T, Edlin R, et al. Access with evidence development schemes: a framework for description and evaluation. Pharmacoeconomics 2010; 28 (2): 143–52

    Article  PubMed  Google Scholar 

  5. Briggs A, Ritchie K, Fenwick E, et al. Access with evidence development in the UK: past experience, current initiatives and future potential. Pharmacoeconomics 2010; 28 (2): 163–70

    Article  PubMed  Google Scholar 

  6. Mohr PE, Tunis SR. Access with evidence development: the US experience. Pharmacoeconomics 2010; 28 (2): 153–62

    Article  PubMed  Google Scholar 

  7. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290 (12): 1624–32

    Article  PubMed  CAS  Google Scholar 

  8. Garrison Jr LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR realworld data task force report. Value Health 2007; 10: 326–35

    Article  PubMed  Google Scholar 

  9. Drummond M, Evans W, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases. A case study in oncology. Can J Clin Pharmacol 2009; 16 (2): e273–81

    PubMed  Google Scholar 

  10. Gooch KL, Smith D, Wasylak T, et al. The Alberta hip and knee replacement project: a model for health technology assessment based on comparative effectiveness of clinical pathways. Int J Tech Assess Health Care 2009; 25: 113–23

    Google Scholar 

  11. MacLeod SM, Bienenstock J. Evidence-based rationing: Dutch pragmatism or government insensitivity? Can Med Ass J 1998; 158: 213–4

    CAS  Google Scholar 

  12. Williams A. What could be nicer than NICE? London: Office for Health Economics, 2004

    Google Scholar 

  13. Hightower J. Theres nothing in the middle of the road but yellow stripes and dead armadillos: a work of political subversion. New York: HarperCollins Publishers, 1997

    Google Scholar 

  14. Chalkidou K, Tunis S, Lopert R, et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 2009; 87: 339–67

    Article  PubMed  Google Scholar 

  15. Eden J, Wheatley B, McNeil B, et al., editors. Committee on reviewing evidence to identify highly effective clinical services. Knowing what works in health care: a roadmap for the nation. Washington, DC: The National Academies Press, 2009

    Google Scholar 

  16. Lomas J. Commentary: whose views count in evidence synthesis? And when do they count? Healthc Policy 2006; 1 (2): 55–7

    PubMed  Google Scholar 

  17. Daniels N. Rationing fairly: programmatic considerations. Bioethics 1993; 7: 223–33

    Article  CAS  Google Scholar 

  18. Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff 1998; 17: 50–64

    Article  CAS  Google Scholar 

  19. Daniels N, Sabin JE. Setting limits fairly: can we learn to share medical resources? New York: Oxford University Press, 2002

    Google Scholar 

  20. Daniels N, Sabin JE. Accountability for reasonableness: an update. BMJ 2008; 337: a1850 [online]. Available from URL: (http://www.bmj.com/cgi/content/extract/337/oct09_1/a1850) [Accessed 2009 Nov 24]

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Child & Family Research Institute, BC Children’s Hospital, University of British Columbia, 4480 Oak Street, Vancouver, V6H 3V4, British Columbia, Canada

    Stuart MacLeod (Executive Director)

  2. Provincial Health Services Authority, Vancouver, British Columbia, Canada

    Stuart MacLeod (Executive Director)

  3. University of British Columbia, Vancouver, British Columbia, Canada

    Stuart MacLeod (Executive Director)

  4. Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada

    Craig Mitton

  5. School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada

    Craig Mitton

Authors
  1. Stuart MacLeod
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig Mitton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart MacLeod.

Rights and permissions

Reprints and permissions

About this article

Cite this article

MacLeod, S., Mitton, C. We Know Accurately Only When We Know Little. Pharmacoeconomics 28, 105–107 (2010). https://doi.org/10.2165/11531510-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11531510-000000000-00000

Search

Navigation